海思科安瑞克芬注射液新适应症获批

Core Viewpoint - The company has received a Class 1 innovative drug registration certificate from the National Medical Products Administration for Anruikefen injection (brand name: Sishujing, R&D code: HSK21542), with a new indication for treating moderate to severe itching related to chronic kidney disease in adult patients undergoing maintenance hemodialysis [1] Group 1 - The drug Anruikefen is now approved for a new indication, expanding its potential market [1] - The approval highlights the company's commitment to developing innovative treatments for chronic conditions [1] - This development may enhance the company's competitive position in the pharmaceutical industry [1]